HC Wainwright Issues Optimistic Estimate for VTVT Earnings

vTv Therapeutics Inc. (NASDAQ:VTVT) – Analysts at HC Wainwright upped their Q2 2026 EPS estimates for vTv Therapeutics in a research note issued on Thursday, May 14th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.64). The consensus estimate for vTv Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for vTv Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at ($3.17) EPS, FY2028 earnings at ($3.45) EPS, FY2029 earnings at ($3.52) EPS and FY2030 earnings at ($3.36) EPS.

VTVT has been the topic of a number of other research reports. Evercore began coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target on the stock. Roth Mkm began coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $49.00 price target on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Research raised shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT opened at $35.49 on Tuesday. The firm has a fifty day moving average price of $35.92 and a 200 day moving average price of $34.27. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm has a market cap of $139.83 million, a price-to-earnings ratio of -38.16 and a beta of 0.26.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics in the 4th quarter worth about $221,000. 683 Capital Management LLC purchased a new position in vTv Therapeutics in the 4th quarter worth about $731,000. Geode Capital Management LLC increased its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP increased its stake in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares during the period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.